Archives

30 October 2018 ASX Announcement Trading and market update Please refer to the following link for a trading and market update – ASX Announcement – Market and Trading Update

Please refer to the following link for the Chairman’s and CEO’s Address to Shareholders, as provided at the 2018 AGM – ASX Announcement – Chairman’s and CEO’s Address to Shareholders (Final)

11 October 2018 ASX Announcement Penthrox is approved in Saudi Arabia Medical Developments International Limited (ASX:MVP), announce today that Penthrox® has been granted Marketing Authorisation in the Kingdom of Saudi Arabia (KSA). The Marketing Authorisation issued by the Saudi Food and Drug Administration (SFDA), is for Penthrox® to be used for Emergency relief of moderate […]

8 October 2018 ASX Announcement MVP signs exclusive Penthrox deal for China with Daiichi Sankyo Medical Developments International Limited (ASX: MVP) is delighted to announce it has entered into an exclusive Distribution and License Agreement with Daiichi Sankyo Company Limited (Daiichi Sankyo) for Penthrox® in China, Thailand and Vietnam. Daiichi Sankyo is listed on the […]

19 September 2018 ASX Announcement Share Purchase Plan Medical Developments International (ASX: MVP) (Company) advises that it has today successfully completed its Share Purchase Plan (SPP) that has resulted in the issue of 1,868,703 fully paid ordinary shares in the Company at a price of $4.00 per fully paid ordinary share, raising $7.475 million (before […]

25 July 2018 ASX ANNOUNCEMENT USA Update Medical Developments International (ASX: MVP) today advised that it met with the Food and Drug Administration (“FDA”) for the United States of America overnight. The FDA has advised that the clinical program for Penthrox to be approved for sale in the USA is to be put on hold […]

16 July 2018 ASX Announcement Penthrox approved in Italy, The Czech Republic and Spain. Medical Developments International Limited (ASX: MVP) is delighted to announce that Penthrox has been approved for sale in Italy, the Czech Republic and Spain. MVP CEO, Mr. John Sharman said, “We are delighted to have received the approval for these countries and we […]

25 June 2018 ASX Announcement Penthrox approved in Portugal and Switzerland. Medical Developments International Limited (ASX: MVP) is delighted to announce that Penthrox has been approved for sale in Switzerland and Portugal. MVP CEO, Mr. John Sharman said, “The roll out of Penthrox across Europe continues. We are delighted to have received the approval from […]

26 February 2018 ASX Announcement Please refer to the attached link for the latest version of the CEO Roadshow Presentation – Road Show March 2018 – MVP

20 February 2018 ASX ANNOUNCEMENT  Stage II success for new manufacturing technology: Lidocaine Medical Developments International Limited (ASX: MVP) is delighted to announce that, in partnership with the CSIRO, it has successfully completed a small-scale production run for Lidocaine using MVP’s new manufacturing technology. Lidocaine has worldwide sales of approximately $3.4 billion. It is a […]